Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 168.39
NVAX's Cash to Debt is ranked higher than
75% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. NVAX: 168.39 )
NVAX' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 168.39

Equity to Asset 0.83
NVAX's Equity to Asset is ranked higher than
85% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. NVAX: 0.83 )
NVAX' s 10-Year Equity to Asset Range
Min: 0.14   Max: 0.96
Current: 0.83

0.14
0.96
F-Score: 3
Z-Score: 22.74
M-Score: -0.97
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -272.97
NVAX's Operating margin (%) is ranked higher than
66% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -85.54 vs. NVAX: -272.97 )
NVAX' s 10-Year Operating margin (%) Range
Min: -11502.46   Max: -38.46
Current: -272.97

-11502.46
-38.46
Net-margin (%) -270.55
NVAX's Net-margin (%) is ranked higher than
65% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. NVAX: -270.55 )
NVAX' s 10-Year Net-margin (%) Range
Min: -12414.15   Max: -40.49
Current: -270.55

-12414.15
-40.49
ROE (%) -35.53
NVAX's ROE (%) is ranked higher than
73% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -32.57 vs. NVAX: -35.53 )
NVAX' s 10-Year ROE (%) Range
Min: -155.17   Max: -26.95
Current: -35.53

-155.17
-26.95
ROA (%) -31.08
NVAX's ROA (%) is ranked higher than
72% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. NVAX: -31.08 )
NVAX' s 10-Year ROA (%) Range
Min: -108.43   Max: -13.76
Current: -31.08

-108.43
-13.76
ROC (Joel Greenblatt) (%) -497.20
NVAX's ROC (Joel Greenblatt) (%) is ranked higher than
73% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. NVAX: -497.20 )
NVAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -872.73   Max: -31.47
Current: -497.2

-872.73
-31.47
Revenue Growth (3Y)(%) 2.50
NVAX's Revenue Growth (3Y)(%) is ranked higher than
78% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: 0.40 vs. NVAX: 2.50 )
NVAX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 160.4
Current: 2.5

0
160.4
EBITDA Growth (3Y)(%) 32.60
NVAX's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 758 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. NVAX: 32.60 )
NVAX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -58.5   Max: 101.4
Current: 32.6

-58.5
101.4
EPS Growth (3Y)(%) 29.60
NVAX's EPS Growth (3Y)(%) is ranked higher than
93% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. NVAX: 29.60 )
NVAX' s 10-Year EPS Growth (3Y)(%) Range
Min: -45.6   Max: 52.3
Current: 29.6

-45.6
52.3
» NVAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

NVAX Guru Trades in Q1 2014

Steven Cohen 192,191 sh (New)
Paul Tudor Jones 29,939 sh (+11.17%)
David Swensen Sold Out
Jean-Marie Eveillard 200,000 sh (-75.00%)
» More
Q2 2014

NVAX Guru Trades in Q2 2014

Paul Tudor Jones 300,000 sh (+902.04%)
Jean-Marie Eveillard 500,000 sh (+150.00%)
» More
Q3 2014

NVAX Guru Trades in Q3 2014

Jean-Marie Eveillard 500,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q4 2014

NVAX Guru Trades in Q4 2014

Jean-Marie Eveillard Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NVAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.00
NVAX's P/B is ranked higher than
61% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 6.46 vs. NVAX: 9.00 )
NVAX' s 10-Year P/B Range
Min: 1.02   Max: 10.71
Current: 9

1.02
10.71
P/S 61.60
NVAX's P/S is ranked higher than
59% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 31.20 vs. NVAX: 61.60 )
NVAX' s 10-Year P/S Range
Min: 5.93   Max: 99999999.99
Current: 61.6

5.93
99999999.99
EV-to-EBIT -21.52
NVAX's EV-to-EBIT is ranked higher than
71% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVAX: -21.52 )
NVAX' s 10-Year EV-to-EBIT Range
Min: -381.5   Max: -1
Current: -21.52

-381.5
-1
Current Ratio 5.52
NVAX's Current Ratio is ranked higher than
77% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. NVAX: 5.52 )
NVAX' s 10-Year Current Ratio Range
Min: 0.69   Max: 14.49
Current: 5.52

0.69
14.49
Quick Ratio 5.52
NVAX's Quick Ratio is ranked higher than
78% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. NVAX: 5.52 )
NVAX' s 10-Year Quick Ratio Range
Min: 0.69   Max: 14.37
Current: 5.52

0.69
14.37
Days Sales Outstanding 89.41
NVAX's Days Sales Outstanding is ranked higher than
77% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 111.38 vs. NVAX: 89.41 )
NVAX' s 10-Year Days Sales Outstanding Range
Min: 16.72   Max: 289.75
Current: 89.41

16.72
289.75

Valuation & Return

vs
industry
vs
history
Price/Net Cash 16.00
NVAX's Price/Net Cash is ranked higher than
71% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 87.00 vs. NVAX: 16.00 )
NVAX' s 10-Year Price/Net Cash Range
Min: 5.54   Max: 96.9
Current: 16

5.54
96.9
Price/Net Current Asset Value 15.40
NVAX's Price/Net Current Asset Value is ranked higher than
71% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 28.08 vs. NVAX: 15.40 )
NVAX' s 10-Year Price/Net Current Asset Value Range
Min: 5.13   Max: 64.6
Current: 15.4

5.13
64.6
Price/Tangible Book 12.70
NVAX's Price/Tangible Book is ranked higher than
58% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 9.40 vs. NVAX: 12.70 )
NVAX' s 10-Year Price/Tangible Book Range
Min: 3.01   Max: 187.5
Current: 12.7

3.01
187.5
Price/Median PS Value 1.30
NVAX's Price/Median PS Value is ranked higher than
82% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. NVAX: 1.30 )
NVAX' s 10-Year Price/Median PS Value Range
Min: 0.09   Max: 4.14
Current: 1.3

0.09
4.14
Earnings Yield (Greenblatt) -4.50
NVAX's Earnings Yield (Greenblatt) is ranked higher than
72% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. NVAX: -4.50 )
NVAX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -5.3   Max: 0
Current: -4.5

-5.3
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NVV.Germany,
Novavax, Inc. was incorporated in 1987 under the laws of the State of Delaware. The Company is a clinical-stage Biopharmaceutical company focused on creating differentiated, value- upon current preventive options for a range of infectious diseases. The Company manages its business as one operating segment: developing recombinant vaccines. The Company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles ('VLPs') and recombinant nanoparticle vaccines combined with a single-use bioprocessing production system. These vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate immunologically important recombinant proteins. Its influenza VLPs contain three of the structural virus proteins that are important for fighting influenza: hemagglutinin (HA) and neuraminidase (NA), both of which stimulate the body to produce antibodies that neutralize the influenza virus and prevent its spread through the cells in the respiratory tract, and matrix 1 (M1), which stimulates cytotoxic T lymphocytes to kill cells that may already be infected. The Company's product pipeline targets a variety of infectious diseases and its vaccine candidates are currently in or have completed clinical trials that target pandemic influenza (H5N1), seasonal influenza and respiratory syncytial virus ('RSV'). The Company's main competitors includes sanofi pasteur, Inc, MedImmune, LLC (a subsidiary of AstraZeneca PLC), GlaxoSmithKline plc, Novartis, Inc., and Merck & Co., Inc., Protein Sciences Corporation. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential federal, state or local regulations.
» More Articles for NVAX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: United States Steel Corp, Tuesday Morning Corp, Novavax Inc. Feb 09 2015 
comment on NVAX Mar 16 2013 
comment on NVAX Mar 16 2013 
Novavax Inc. Reports Operating Results (10-Q) Nov 08 2010 
Novavax Inc. Reports Operating Results (10-Q) Aug 06 2010 
Novavax Inc. Reports Operating Results (10-Q) May 10 2010 
creiter note on NVAX Jan 03 2010 
Novavax Inc. Reports Operating Results (10-Q) Nov 10 2009 
Novavax Inc. Reports Operating Results (10-Q) Aug 11 2009 
Novavax Reports Second Quarter 2009 Financial Results Aug 07 2009 

More From Other Websites
1:38 am Novavax presents new data from non-human primate Ebola challenge Mar 30 2015
Novavax Presents New Data From Non-Human Primate Ebola Challenge at the 7th International Symposium... Mar 28 2015
NOVAVAX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial... Mar 27 2015
Novavax Gives Wall Street Underwriters A Sweet Deal Mar 27 2015
Novavax Prices Public Offering of Common Stock Mar 26 2015
Novavax (NVAX) Stock Declines Today After Announcing $175 Million Public Stock Offering Mar 25 2015
Novavax Announces Proposed Public Offering of Common Stock Mar 24 2015
FDA panel to discuss Ebola vaccine development in May Mar 18 2015
Apple CEO Tim Cook surprises Jim Mar 12 2015
Novavax Appoints Brian Rosen as Vice President, Government Affairs Mar 10 2015
NOVAVAX INC Financials Mar 05 2015
10-K for Novavax, Inc. Mar 02 2015
NOVAVAX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 27 2015
NOVAVAX INC Files SEC form 10-K, Annual Report Feb 27 2015
Novavax reports 4Q loss Feb 27 2015
Novavax reports 4Q loss Feb 27 2015
Novavax Reports Fourth Quarter and Year-End 2014 Financial Results Feb 26 2015
Q4 2014 Novavax Inc Earnings Release - After Market Close Feb 26 2015
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial Results on... Feb 19 2015
Novavax Boosted by Ebola Vaccine Data Feb 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK